• +1-646-491-9876
    • +91-20-67278686

    Search

    Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

    Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

    • Report Code ID: RW0001492636
    • Category Pharmaceuticals
    • No. of Pages 108
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.

    Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsenic, and infections. Treatment includes removing the bladder or treating the bladder with radiation and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Muscle Invasive Bladder Cancer (MIBC).

    Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
    - The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Muscle Invasive Bladder Cancer (MIBC) Overview 7
    Therapeutics Development 8
    Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview 8
    Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis 9
    Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies 10
    Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Investigation by Universities/Institutes 11
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance 12
    Late Stage Products 12
    Clinical Stage Products 13
    Early Stage Products 14
    Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies 15
    Muscle Invasive Bladder Cancer (MIBC) - Products under Investigation by Universities/Institutes 16
    Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development 17
    Argos Therapeutics Inc 17
    Astellas Pharma Inc 18
    Astex Pharmaceuticals Inc 19
    AstraZeneca Plc 20
    Cold Genesys Inc 21
    F. Hoffmann-La Roche Ltd 22
    MedImmune LLC 23
    Oncolytics Biotech Inc 24
    Sillajen Biotherapeutics 25
    Taris Biomedical LLC 26
    Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment 27
    Assessment by Monotherapy Products 27
    Assessment by Combination Products 28
    Assessment by Target 29
    Assessment by Mechanism of Action 31
    Assessment by Route of Administration 33
    Assessment by Molecule Type 35
    Drug Profiles 37
    atezolizumab - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    AZD-1775 + durvalumab - Drug Profile 50
    Product Description 50
    Mechanism Of Action 50
    R&D Progress 50
    AZD-4547 - Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    Cellular Immunotherapy for Oncology - Drug Profile 53
    Product Description 53
    Mechanism Of Action 53
    R&D Progress 53
    CG-0070IT - Drug Profile 54
    Product Description 54
    Mechanism Of Action 54
    R&D Progress 54
    durvalumab - Drug Profile 55
    Product Description 55
    Mechanism Of Action 55
    R&D Progress 55
    erlotinib hydrochloride - Drug Profile 65
    Product Description 65
    Mechanism Of Action 65
    R&D Progress 65
    gemcitabine hydrochloride - Drug Profile 69
    Product Description 69
    Mechanism Of Action 69
    R&D Progress 69
    guadecitabine - Drug Profile 70
    Product Description 70
    Mechanism Of Action 70
    R&D Progress 70
    MTG-202 - Drug Profile 76
    Product Description 76
    Mechanism Of Action 76
    R&D Progress 76
    pelareorep - Drug Profile 77
    Product Description 77
    Mechanism Of Action 77
    R&D Progress 77
    pexastimogene devacirepvec - Drug Profile 90
    Product Description 90
    Mechanism Of Action 90
    R&D Progress 90
    rocapuldencel-T - Drug Profile 97
    Product Description 97
    Mechanism Of Action 97
    R&D Progress 97
    Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects 104
    Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones 105
    Featured News & Press Releases 105
    Jul 13, 2016: TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Muscle-Invasive Bladder Cancer 105
    Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN 105
    Appendix 107
    Methodology 107
    Coverage 107
    Secondary Research 107
    Primary Research 107
    Expert Panel Validation 107
    Contact Us 107
    Disclaimer 108

    List of Tables

    Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
    Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
    Number of Products under Development by Companies, H2 2016 10
    Number of Products under Investigation by Universities/Institutes, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Clinical Stage Development, H2 2016 13
    Comparative Analysis by Early Stage Development, H2 2016 14
    Products under Development by Companies, H2 2016 15
    Products under Investigation by Universities/Institutes, H2 2016 16
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
    Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
    Assessment by Monotherapy Products, H2 2016 27
    Assessment by Combination Products, H2 2016 28
    Number of Products by Stage and Target, H2 2016 30
    Number of Products by Stage and Mechanism of Action, H2 2016 32
    Number of Products by Stage and Route of Administration, H2 2016 34
    Number of Products by Stage and Molecule Type, H2 2016 36
    Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104

    List of Figures

    Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
    Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
    Number of Products under Development by Companies, H2 2016 10
    Comparative Analysis by Clinical Stage Development, H2 2016 13
    Comparative Analysis by Early Stage Products, H2 2016 14
    Assessment by Monotherapy Products, H2 2016 27
    Number of Products by Top 10 Targets, H2 2016 29
    Number of Products by Stage and Top 10 Targets, H2 2016 29
    Number of Products by Top 10 Mechanism of Actions, H2 2016 31
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 31
    Number of Products by Routes of Administration, H2 2016 33
    Number of Products by Stage and Routes of Administration, H2 2016 33
    Number of Products by Molecule Types, H2 2016 35
    Number of Products by Stage and Molecule Types, H2 2016 35
    Argos Therapeutics Inc
    Astellas Pharma Inc
    Astex Pharmaceuticals Inc
    AstraZeneca Plc
    Cold Genesys Inc
    F. Hoffmann-La Roche Ltd
    MedImmune LLC
    Oncolytics Biotech Inc
    Sillajen Biotherapeutics
    Taris Biomedical LLC

    Request for Sample

    Report Url http://www.reportsweb.com//muscle-invasive-bladder-cancer-mibc-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//muscle-invasive-bladder-cancer-mibc-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//muscle-invasive-bladder-cancer-mibc-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments